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Mitochondrial permeability transition pore
Cyclophilin D
Cyclosporine AAmyloid beta (Aβ) plays a critical role in the pathophysiology of Alzheimer's disease. Increasing evidence
indicates mitochondria as an important target of Aβ toxicity; however, the effects of Aβ toxicity on
mitochondria have not yet been fully elucidated. Recent biochemical studies in vivo and in vitro implicate
mitochondrial permeability transition pore (mPTP) formation involvement in Aβ-mediated mitochondrial
dysfunction. mPTP formation results in severe mitochondrial dysfunction such as reactive oxygen species
(ROS) generation, mitochondrial membrane potential dissipation, intracellular calcium perturbation,
decrease in mitochondrial respiration, release of pro-apoptotic factors and eventually cell death. Cyclophilin
D (CypD) is one of the more well-knownmPTP components and recent ﬁndings reveal that Aβ has signiﬁcant
impact on CypD-mediated mPTP formation. In this review, the role of Aβ in the formation of mPTP and the
potential of mPTP inhibition as a therapeutic strategy in AD treatment are examined.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer disease (AD), a commonly occurring progressive neuro-
degenerative disorder in aged people results in severe cognitive
deﬁcits [1,2] with typical pathological changes such as amyloid beta
(Aβ) deposition in brain parenchyma and vessels [3–6], neuroﬁbril-
lary tangles formation [7–10], and neuronal loss. Even though a small
percentage of the patients carry AD associated genetic mutants,
approximately 98% of AD onset occurs in a sporadic manner and the
mechanism of AD pathogenesis remains largely unknown. Among the
reported possible pathogenic factors for AD, extracellular as well as
intracellular Aβ [11,12] is considered to play a central role. It remains
unclear, however, which type of Aβ species plays a major role and
whether Aβ is the initiating factor in AD. Aβ is reported to impact a
diverse array of cellular properties, including disruption of cell
membrane integrity, and disturbance of organelle function and
intracellular homeostasis. Despite its various impacts on neurons,
increasing evidence is focused on Aβ-mediated mitochondrial
dysfunction in AD. Known Aβ related mitochondrial dysfunctions
including mitochondrial DNA mutation [13–15], decreased glucose
metabolism [16, 17], decreased mitochondrial respiratory chaindisease; mPTP, mitochondrial
AC, voltage-dependent anion
cyclosporine A; ROS, reactive
ll rights reserved.activity [18,19], deactivation of certain key enzymes [16,18–22],
increased reactive oxygen species (ROS) generation [18,19,23–30]
and perturbed calcium homeostasis [18,22,31–33] have been widely
observed in AD patients, AD animal models and in Aβ-treated cell
cultures. Recent studies have demonstrated that Aβ induced mito-
chondrial dynamic changes, including decrease in mitochondrial
movement and mitochondrial ﬁssion/fusion perturbations [34,35].
These observations signiﬁcantly increase our understanding of mito-
chondrial perturbation relevant to the pathogenesis of AD. Further-
more, progressive accumulation of mitochondrial Aβ in the AD brain
and in the ADmouse model implicates the role of mitochondrial Aβ in
mitochondrial malfunction [16,18,20,27,36]. Although the precise role
of Aβ in mitochondria is not yet deﬁned, reports clearly show that
interaction of mitochondrial Aβ with mitochondrial proteins, amy-
loid-beta (Aβ) binding alcohol dehydrogenase (ABAD) and cyclophilin
D exacerbates mitochondrial and neuronal stress in transgenic AD
mouse models [16,18,22,27].
Notably, the involvement of mitochondrial permeability transition
pore (mPTP) is implicated in Aβ-induced mitochondrial dysfunction,
such as perturbation of intracellular calcium regulation, ROS genera-
tion, release of pro-apoptotic factors and changes in mitochondrial
morphology. This assumption is deduced from the facts that calcium
and ROS are strong inducers of the mPTP formation and that the
consequences of mPTP formation are increased ROS generation,
decreased ATP production and apoptogenic substance release accom-
panied bymitochondrial swelling [37–40]. For instance, the absence of
cyclophilin D, a key component ofmPTP, protects against Aβ-mediated
mitochondrial, neuronal and synaptic dysfunction [18,22]. These
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mechanism of Aβ toxicity as well as AD pathogenesis. This review
contains a discussion of the role of Aβ-induced mPTP formation in the
induction of mitochondrial dysfunction and its relevance to the
pathogenesis of AD.
2. Mitochondria and mitochondrial permeability transition pore
(mPTP)
Mitochondria are pivotal organelles in all eukaryotic cells and play
a vital role in cell survival by providing energy, maintaining intra-
cellular calcium homeostasis and regulating cellular redox status.
Another important role of mitochondria in cell survival is as an
initiating organelle for apoptosis due to its ability to release apop-
togenic factors in response tomitochondrial stress. The basic structure
of a mitochondrion consists of the outer mitochondrial membrane
(OMM), the inner mitochondrial membrane (IMM) [41] and the
matrix. OMM is quite permeable to ions, solutes and even some small
proteins, while IMM is impermeable to most ions and solutes. The
impermeable property of IMM is important in maintaining home-
ostasis of the inner mitochondrial environment as well as its
morphology, while blocking the free exchange of substances between
matrix and cytosol. The exchange (especially the import) of mito-
chondria with their outer environment is strictly controlled by the
channels and transporters in the IMM. Any disturbance in this control
can lead to mitochondrial damage. For example, cytosolic calcium
cannot freely move into mitochondria in an ion gradient driven
manner but does so via the energy driven uniporter [42,43]. On the
other hand, the extrusion of calcium frommitochondria under normal
conditions is mainly achieved via antiporter driven by ion gradient
[44]. In the circumstances of mitochondrial calcium or phosphate
overloading, and intracellular oxidative stress, mitochondria lose their
calcium handling ability and intramitochondrial calcium quickly
efﬂuxes via a nonselective pathway, named mitochondrial perme-
ability transition pore (mPTP) [45–48].
2.1. The molecular basis of mPTP
Although the presence of mPTP formation has long been proposed
andwidely proven, until recent years themolecular basis of mPTPwas
not clearly delineated. The structure of the pore is believed to be
composed of three compartments: voltage-dependent anion channel
(VDAC) in the OMM [49], adenine nucleotide translocator (ANT) in
the IMM [50] and cyclophilin D (Cyp D) in the mitochondrial matrix
[40]. According to the prevailing point of view, the formation of the
pore is initiated by the CypD translocation from the mitochondrial
matrix to the IMM to bind with ANT. CypD binding to ANT results in
the formation of an ANT channel in IMM. The ANT formed channel
together with the channel formed by VDAC in OMM constitutes a
tunnel-like structure crossing the mitochondrial membranes, thus
connecting mitochondrial matrix with the cytosol [49,51]. Studies in
animal models have shown that the mPTP formation can be efﬁciently
blocked by the addition of a cyclophilin D inhibitor, cyclosporine A
(CSA) or by ablation of Cyp D [40,51,52].
Despite this considerable evidence supporting the molecular basis
of mPTP, the roles of VDAC and ANT in pore formation have been
challenged in recent studies. In their investigation of VDAC knockout
mice, Krauskopf et al. did not ﬁnd decreased mPTP formation in the
presence of calcium [53]. Baines et al. observed an indispensable role
of VDAC [54] in the formation of mPTP. Their data suggesting that
channel in OMM formed by VDAC allow nonspeciﬁc transport of
substances below a certain size. Another study performed by
Kokoszka et al. on ANT gene ablation mice suggests that ANT deﬁ-
ciency does not contribute signiﬁcantly to the prevention of mPTP
formation [55]. Considering the impermeability of IMM, it is impor-
tant to clarify the mPTP compartment in IMM. A recent study per-formed by Leung et al. proposes a candidate molecule in IMM, called
phosphate carrier (PiC) [56]. This group found that PiC can form a pore
either by itself or in association with ANT, suggesting that PiC but not
ANT is the necessary component of mPTP. Intriguingly, CypD binding
is also sufﬁcient, but not necessary an initiating step for PiC associated
pore opening. In fact, high concentrations of calcium alone can trigger
PiC. These data may provide an explanation for the failure of VDAC or
ANT ablation to prevent mPTP. In addition, these results implicate the
presence of independent non-CypD mPTP formation which can be
triggered by high concentrations of calciumwithout the facilitation of
CypD. Whereas there are disagreements about whether VDAC and
ANT are necessary, it is generally accepted that CypD is a necessary
compartment for mPTP formation, especially in the most commonly
occurring scenarios when calcium levels are not high enough to
trigger the CypD independent mPTP formation.
2.2. Consequences of mPTP formation
Once formed, mPTP constitutes a non-selective, high conductance
pore allowing transport of not only calcium but any solute below the
pore size. This results in mitochondrial osmotic swelling and
dissipation of mitochondrial membrane potential as well as damage
to the mitochondrial respiratory chain thereby reducing mitochon-
drial oxidative phosphorylation process that then results in decreased
ATP production and increased ROS generation. Mitochondrial swelling
leads to ruptures in the OMM, which in turn allows the release of
apoptogenic factors from the mitochondria into the cytosol. It can
therefore be concluded that massive formation of mPTP under patho-
logical conditions causes severe mitochondrial injury and cell death.
Several agents such as CSA [18,57], Sanglifehrin A (SfA) [58] and ADP
[50] are reported to have the potential to inhibit mPTP formation and
ameliorate the consequences of mPTP formation.
Based on the ﬁndings in the preceding paragraphs, one may
conclude that CypD is the most important initiating molecule for
mPTP, and that mPTP formation results in severe mitochondrial
dysfunction, irreversible cell damage and ﬁnally cell death.
3. Amyloid beta (Aβ) and mPTP
Aβ is the product of amyloid precursor protein [59] cleaved by β
and γ secretase. Massive deposition of Aβ is a hallmark change in AD
brain; extracellular and intracellular accumulation of Aβ as well as its
aggregated forms renders severe damages to neurons. Results of
studies regarding Aβ neurotoxicity show that Aβ affects cellular
damages primarily through inducing free radicals and calcium dys-
regulation, both of which have been widely reported in the literature
in both in vitro and in vivo studies. The synergistic impacts of
increased ROS and calcium perturbation lead to fatal cell damage. Aβ
generates oxidizing products during its aggregation [28]. These oxi-
dizing products as well as Aβ itself affect the functions of sodium-
potassium ATPase and calcium ATPase [60,61], which in turn cause
dysregulation of L type voltage sensitive calcium channel (LVSCC)
[62,63], α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
receptor (AMPAR) [64], N-methyl D-aspartate receptor (NMDAR)
[65] and inositol 1,4,5-trisphosphate receptors [66,67] that then
mediate signiﬁcantly increased calcium ﬂux into the cytosol. This
increased intracellular calcium causes mitochondrial calcium over-
loading resulting in an elevation of mitochondrial ROS production.
Both exogenous ROS induced by Aβ and mitochondrial originated ROS
act upon mitochondria mediating further mitochondrial calcium
perturbation and ROS generation.
Several lines of investigation have indicated that free radicals and
calcium are potent inducers of mPTP formation. Based on the
signiﬁcant Aβ-induced ROS formation and calcium perturbations as
noted above, the conditions for mPTP formation are ideal in an Aβ-
rich environment; it is therefore logical to hypothesize that massive
Fig. 1. Cyclophilin D expression levels. Mitochondria were prepared (A) from indicated
brain regions of human AD/non-AD (n=9–12 per group) or (B) from cortices of the
indicated mice at different ages (n=6–10 per group). Isolated mitochondria were then
subjected to SDS-PAGE followed by the addition of anti cyclophilin D Ig G. The
cyclophilin D expression level was normalized with cytochrome c oxidase. ⁎Pb0.05.
Figures are cited from [18].
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several studies [18,19,29,41,68–70] suggest the involvement of mPTP
formation in Aβ-induced neuronal and mitochondrial stress as
evidenced by disrupted mitochondrial membrane potential,
increased production of ROS generation and mitochondrial swelling
and increased cytochrome c release. Aβ-mediated abnormalities
in mitochondrial function are rescued by the addition of the
mPTP inhibitor, CsA or by the genetic blockade of CypD, which
conﬁrms the role of mPTP in this pathological process and stimulates
interest in elucidating the exact mechanism of Aβ stimulated mPTP
formation.
As discussed above, the role of Aβ in mediating ROS generation,
calcium dysregulation and the resultant mitochondrial respiration
failure establishes mitochondria as the ‘victim’ in mPTP formation.
Studies by Parks et al. adopting in vivo investigation indicate that Aβ
induces free radicals through mechanisms involving the NMDA re-
ceptor and nitric oxide synthase [41]. Our own studies found increased
mitochondrial ROS, decreased cytochrome c oxidase activity and
declined mitochondrial respiration control ratio in an AD-type animal
model as compared with their wild type littermates (controls)
[18,20,22]. Notably, mitochondrial function is largely recovered in
CypD-deﬁcient AD-type mice overexpressing human mutant APP/Aβ.
Neurons lacking CypD or CSA-treated neurons are quite resistant to Aβ
insults, showing fewer apoptotic cells, improved mitochondrial
membrane potential and decreased cytochrome c release in compar-
ison with cultured neurons from nontransgenic littermate controls
[18,22]. Taken together, these studies offer strong evidence that ROS
and calcium dysregulation induced by Aβ are involved in mPTP
formation.
4. Cyclophilin D involves in Aβ-mediated mPTP perturbation
4.1. Expression of CypD in AD brain and from mAPP mice
In view of the known key role of CypD in mPTP function, inves-
tigation was undertaken to assess whether alternations in CypD
expression are associated with AD pathology. Findings revealed that
expression of CypD was signiﬁcantly elevated in Aβ-containing
cortical mitochondria from AD-affected regions (temporal pole and
hippocampus) as compared to non-AD cortical mitochondria of
age-matched non-AD patients. There was no signiﬁcant difference in
CypD expression in cerebellum between human AD and non-AD
brains (Fig. 1A). Furthermore, increased levels of CypD in AD correlate
to the presence of mitochondrial Aβ in AD brains [18]. Consistent with
the observations of human AD brain, transgenic (Tg) mice expressing
a mutant form of human amyloid precursor protein (mAPP mice)
displayed an age-dependent elevated level of CypD in the cerebral
cortex (including the hippocampus) as compared with nontransgenic
(nonTg) littermate controls (Fig.1B) [18,22]. These results suggest that
alternations in CypD expressionmay impact the pathogenesis of AD in
addition to its known role in age-related cellular perturbation.
Given the fact that Cyp D is the critical molecule inmPTP formation
and CypD ablation prevents mPTP formation, it has been proposed
that increased CypD level favors the opening of mPTP [18,22,71,72].
Recent studies indicate that high levels of CypD in neuronal
mitochondria increase vulnerability to mPTP and require higher levels
of CSA to inhibit mPTP opening [73]. In contrast, neuronal cells with
decreasing levels of CypD become less sensitive to mPTP induction.
Previous studies from our laboratory demonstrate that mAPP cortical
mitochondria have a higher level of CypD as well as increased CypD
translocation to the IMM, calcium-induced mitochondrial swelling
and decreased calcium buffering capacity. These deleterious effects on
mitochondrial properties are largely blocked by CypD deletion and the
addition of CSA [18,22]. This indicates that increased CypD level in
mAPP mice leads to decreased mPTP formation threshold, although
these data should be interpreted with reservation since existingmitochondrial dysfunction in mAPP mice may be a factor in
mitochondrial response to calcium. Furthermore, neuronal cells stably
overexpressing CypD demonstrate exacerbated mitochondrial mal-
function caused by oxidative stress and Aβ insults (unpublished
observations, Du, H and Yan, SD) compared to mock-transfected cells.
These data indicate that modulation of CypD expression may lead to
the functional changes in mPTP under pathological conditions. Aβ- or
oxidative stress-induced increases in CypD expression may therefore
contribute to impaired mPTP function/formation in an environment
enriched for amyloid pathology, such as AD.
4.2. Aβ interacts with CypD
Results of in vitro binding assays [using surface Plasmon resonance
(SPR) and recombinant human CypD protein] undertaken to deter-
mine if Aβ binds to CypD, revealed that oligomeric Aβ40 and Aβ42
have higher afﬁnity for binding to CypD than does monomeric Aβ. It is
now known that interactions between Aβ and CypD are speciﬁc
because sequence reversed Aβ peptide showed no binding with CypD
and antibodies against either Aβ or CypD inhibited the binding
[18,22]. To determine if CypD and Aβ interact in pathologically
relevant settings, we performed immunoprecipitation-immunoblot-
ting studies. The data suggested the Aβ-CypD complex in AD brain
tissues and mAPP mice brains; whereas, as expected in age-matched
non-AD brains with undetectable or low levels of cerebral Aβ, there
was virtually no detectable or very low level of CypD–Aβ complex.
Formation of Aβ-CypD complex is associated with mitochondrial Aβ
level in the AD brain [18].
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by confocal and electron microscopy by showing that α-Aβ and α-
CypD are extensively colocalized in the cerebral cortex of AD patients
or mAPP mice [18]. These results provide further evidence that the
CypD–Aβ interaction occurs within mitochondria in vivo.
4.3. Blockade of CypD protects against Aβ-induced mitochondrial and
neuronal toxicity
CypD plays a key role in stabilizing mitochondrial permeability
transition (mPT) and serves to open the mitochondrial permeability
transition pore (mPTP), thereby allowing the diffusion of contents such
as calcium and cytochrome c out of mitochondria matrix to the cyto-
plasm where they may induce cell death via necrosis and apoptosis. It
was therefore important to examine the effect of CypD deletion on
mitochondrial properties in an Aβ-rich environment, including the
capacity for Ca2+ uptake, mPT,membrane potential and ROS generation.
Assessment of Ca2+ uptake capacity of cortical mitochondria by
measuring the decrease in extra-mitochondrial free Ca2+ from the
medium after the addition of CaCl2 pulses revealed that changes in
calciumuptake capacity occurred in an age-dependentmanner in both
nonTg and mAPP mice. When compared to mice aged 3 to 6 months,
nonTg mice showed a trend toward reduction of calcium uptake
capacity by up to 22–24 months old; of note, however, mAPP mice
showed a decreased brain mitochondrial calcium uptake capacity as
compared to nonTgmice (Fig. 2A). At 3 months of age, both nonTg and
mAPP mice possess adequate calcium buffering capacity. In contrast,
impaired capacity for Ca2+ uptake begins at 6 months of age andFig. 2. Age-dependent mitochondrial calcium retention capacity (CRC) change: (A)
Brain mitochondrial CRC was compared between nonTg and mAPP mice at 3, 6, 12 and
24 months of age (n=4–6). Substantially decreased CRC of mAPP mitochondria in
comparison to other genotypes was detected after the age of 6 months. ⁎Pb0.05. (B)
CRC was compared between brain mitochondria from the indicated mice at the ages of
12 and 24 months, respectively (n=4–6 for each group). mAPP mitochondria were
treated with cyclosporine A (1 μM). ⁎, #: Pb0.05 vs. other genotypes of mice. Figures are
cited and conﬂated from [18,22].progressively decreased in 12 and 22–24-month-old mAPP mice with
reductions of ∼18%, ∼50%, and ∼58%, respectively, as compared to the
3-month-old mAPP mice (Fig. 2A). Importantly, cortical mitochondria
from CypD-deﬁcient mAPP mice (mAPP/Ppif−/−) demonstrate rela-
tively more Ca2+ uptake at the mice ages of 6, 12, and 22–24 months,
respectively, when compared to mAPP mitochondria. Similarly, mAPP
cortical mitochondria treated with CSA demonstrate a protection on
mitochondrial Ca2+ uptake capacity (Fig. 2B).
To determine the effect of mPTP on calcium handling ability of Aβ-
rich mitochondria from mAPP mice, the next logical step includes
measurement of mitochondrial swelling in response to Ca2+. Cortical
mitochondria from transgenic and nonTg mice showed swelling in
response to Ca2+, whereas mAPP mitochondria displayed increased
swelling compared to nonTg mitochondria at the mice ages of 12 and
22–24 months although both cortical mitochondria of nonTg and
mAPP mice exhibited an age-dependent increased swelling in
response to Ca2+ (Fig. 3) [18,22]. Importantly, CypD-deﬁcient mAPP
mitochondria (mAPP/Ppif−/−) were more resistant to swelling and
permeability transition induced by Ca2+ than mAPP mitochondria
(Fig. 3) [18,22]. The addition of CSA to the mAPP mitochondria also
attenuated swelling in response to Ca2+ (Fig. 3) [18,22]. The inhibitory
effect of CSA on Ca2+-induced swellingwas comparable to those of the
mAPP/Ppif−/− mice. Taken together, these results indicate that Aβ-
rich cortical mitochondria are more susceptible to Ca2+-induced
mPTP, and that blockade of CypD protects against Aβ-mediated dys-
function of mPTP, suggesting a role for Aβ-CypD interaction in mPTP.
To fully evaluate mitochondrial function, we measured the inner
mitochondrial membrane potential (ΔΨm) in brain slices in situ. Brain
slices from Tg mice were loaded with tetramethylrhodamine methyl
ester (TMRM) to assess inner mitochondrial ΔΨm. The intensity of
TMRM staining was signiﬁcantly decreased in the cerebral cortices
and hippocampi from 12-month-old mAPP mice compared to nonTg
mice. In contrast, mitochondria from CypD-deﬁcient mAPP mice were
largely resistant to the loss of ΔΨm demonstrating a higher TMRM
staining intensity compared to mitochondria from single mAPP mice
[18]. Thus, the ΔΨm of mitochondria lacking CypD is protected from
Aβ-mediated swelling and opening of the membrane permeability
transition pore.
As mitochondria are the principal sites of generation of ROS, and
Aβ is known to trigger oxidative stress, we tested whether CypD–Aβ
interaction correlates with ROS generation in mitochondria. To eval-
uate mitochondrial ROS generation, mice were injected intravenously
with MitoSox Red, a novel ﬂuorogenic dye for highly selective detec-
tion of superoxide production in the mitochondria of live cells. The
percentage of area occupied byMitoSox Red stainingwas increased 2–
3-fold in the cerebral cortices and hippocampi (CA1 to CA3) of mAPPFig. 3. Age-dependent mitochondrial swelling change in response to calcium. Brain
mitochondria isolated from the indicated mice at 3, 6, 12 and 24 months old (n=4–10
for each group) were subjected to measured swelling induced by calcium (500 nmol/
mg mitochondrial fraction). Decreased amplitude (percentage of initial OD at 540 nm)
at the end of the test was compared among groups. 1 μM cyclosporine Awas used in the
treatment of mAPP mitochondria. ⁎Pb0.05. Figures are cited and conﬂated from [18,22].
Fig. 4. Schematic ﬁgure: Aβ increases cyclophilin D expression level and interacts with
cyclophilin D. Furthermore, Aβ is involved in intracellular calcium and ROS perturba-
tions and mitochondrial respiration dysfunction. By decreasing the threshold of mPTP
due to these effects, Aβ facilitates the formation of mPTP resulting in mitochondrial
perturbations including increased ROS generation, exacerbated perturbation of calcium
metabolism and mitochondrial membrane potential collapse. These severe mitochon-
drial perturbations lead tomultiple cellular stresses, neuron death and ﬁnally deﬁcits in
learning/memory ability.
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mice) [18]. These data indicate that the absence of CypD protects from
Aβ-mediated mitochondrial ROS generation.
Assessments of mitochondrial function by examining oxygen
consumption, the activity of cytochrome c oxidase, a key enzyme in
the respiratory chain and level of ATP in the brain of various Tg
mice were then undertaken. The mitochondrial respiratory rate, as
assessed by the respiratory control ratio (ratio of oxygen consumption
in state III/state IV), was signiﬁcantly reduced in brain mitochondria
of mAPP mice as compared to their nonTg littermates, whereas CypD-
deﬁcient mAPP mice showed completely or largely rescued reduction
of oxygen consumption at the ages of 6 to 24months [18,22]. Similarly,
as previously reported [16,20] that mAPP mice had depressed
respiratory function deteriorating with age, we found that mAPP
mice showed decreased cytochrome c oxidase activity and impaired
energymetabolism as shown by a reduction in ATP levels compared to
nonTg controls at 12 to 24 months of age, while the cytochrome c
oxidase activity and ATP level in nonTgmicewere comparable to those
found in CypD-deﬁcient mice, suggesting that deletion of CypD does
not interfere with mitochondrial function under physiologic condi-
tions. Importantly, double mAPP/Ppif−/− mice showed signiﬁcantly
increased mitochondrial enzyme activity (up to 40–50%) and abro-
gated reduction of ATP as compared to mAPP mice [18,22], indicating
that, in an Aβ-rich environment, blockade of CypD attenuates or
protects against Aβ-mediated mitochondrial dysfunction.
4.4. Blockade of CypD improves synaptic function and learning memory
in an AD mouse model
Alterations in mitochondrial properties and perturbation of energy
metabolism and free radical generation in mAPP mice may correlate
with synaptic and neuronal dysfunction. There are strong protective
effects of CypD deﬁciency on Aβ-mediated mitochondrial and
neuronal toxicity. It was therefore important to determine whether
CypD deﬁciency improves synaptic function, learning and memory. In
the radial arm water maze test that detects hippocampus-dependent
learning andmemory deﬁcits, CypD-deﬁcient and nonTgmice showed
strong learning and memory capacity at the ages of 6, 12 and 24
months [18,22], suggesting that there are no deleterious effects of
CypD deﬁciency on normal physiological function. In contrast, mAPP
mice displayed impaired spatial learning memory for platform
location between trials (average of about 5–6 errors by trials 4 and
retention test). Spatial learningmemory was signiﬁcantly improved in
double mAPP/Ppif−/− mice (∼2–3 errors) compared to mAPP mice
(∼5–6 errors by trials 4 or 5) [18,22]. The four groups of transgenic
mice showed no difference in swimming speed or in the time required
to reach the platform in the visible platform test. These results
indicate that improvement in learning and memory is a consequence
of CypD deﬁciency in mAPP mice.
Cognitive abnormalities in AD are thought to be linked to synaptic
dysfunction [74]. As mAPP/Ppif−/− mice showed improvement in
learning and memory, studies were then undertaken to determine
whether these mice also showed improvement of long-term potentia-
tion (LTP), a form of synaptic plasticity that is widely studied as a
cellular model for learning andmemory. Slices from 12–13-month-old
mAPP mice showed a reduction in LTP compared to slices from nonTg
littermates [18], while slices from mAPP/Ppif−/− mice displayed
improved LTP, thereby indicating that depletion of CypD may protect
against the Aβ synaptotoxicity.
5. Targeting CypD inhibition is a potential approach to prevent
and treat AD
Increasing evidence indicates that Aβ-mediated mitochondrial
dysfunction plays a critical role in the pathogenesis of AD. Aβ has
global effects on mitochondrial function, including decreased mito-chondrial respiratory function, diminished mitochondrial key en-
zymes activities, induced mtDNA mutants and ROS generation,
causing calcium perturbation, triggering mPTP formation and even-
tually neuronal damage. Therefore, defeating Aβ at mitochondrial site
is a practical preventive as well as therapeutic strategy for Alzheimer's
disease. However, it should be mentioned that current knowledge
about Aβ-mediated mitochondrial dysfunction still quite limits the
ability to elucidate an effective and efﬁcient strategy to fully prevent
Aβ toxicity onmitochondria. Many approaches used to date have been
developed to prevent mitochondria from Aβ-induced damage,
including eliminating ROS [59,75], enhancing Aβ clearance [76,77]
and stabilizing calcium homeostasis [78,79]. Compared to those
strategies that mainly focus on keeping mitochondria from insults
by eliminating damage causative factors, studies about blocking
massive mPTP formation are at an advantage as they focus on
increasing mitochondrial resistance to existing harmful insults. New
insights into mitochondrial permeability transition pore and Aβ
enable us to delve into AD pathogenesis to ﬁnd efﬁcient ways to
protect mitochondria. CypD inhibition is a feasible and possibly
signiﬁcant therapeutic approach. Cyclosporine A, an inhibitor of CypD
broadly used in a clinical application, might be a potential therapeutic
option for the treatment of AD. However, in terms of the potential
toxic effects of CSA, such as the immunosuppressive effect [80], the
usage of CSA in the treatment of AD would be likely limited. Searching
for a novel agent that selectively targets CypD, mPTP or a mimetic of
CSA without toxic effects is still a rational approach to AD therapy.
6. Conclusions
Aβ mitochondrial toxicity has been intensively studied, whereas
the precise mechanism(s) is largely unknown. The development of
203H. Du, S.S. Yan / Biochimica et Biophysica Acta 1802 (2010) 198–204research on the involvement of Aβ in mPTP formation enhances our
knowledge regarding Aβ associated mitochondrial toxicity and adds
to our knowledge base of aforementioned mechanism(s) of Alzhei-
mer's disease. Aβ–CypD interaction promotes the formation of mPTP,
leading to mitochondrial and neuronal stresses. The absence of CypD
protects against Aβ-induced mPTP formation and the resultant
mitochondrial/cellular stresses, as well as impaired learning memory
(Fig. 4). Thus, the blockade of CypD or mPTP formation may be a
candidate approach for prevention and treatment of AD.
Acknowledgements
This work was supported by the USPHS (PO1 AG17490) and
Alzheimer Association.
References
[1] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, Clinical
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human Services Task Force on
Alzheimer's Disease, Neurology 34 (1984) 939–944.
[2] R.D. Terry, R. Katzman, Senile dementia of the Alzheimer type, Ann. Neurol. 14
(1983) 497–506.
[3] D.J. Selkoe, M.B. Podlisny, C.L. Joachim, E.A. Vickers, G. Lee, L.C. Fritz, T. Oltersdorf,
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-
kilodalton membrane-associated proteins in neural and nonneural tissues, Proc.
Natl. Acad. Sci. U. S. A. 85 (1988) 7341–7345.
[4] D.J. Selkoe, Aging, amyloid, and Alzheimer's disease, N. Engl. J. Med. 320 (1989)
1484–1487.
[5] D.M. Walsh, D.M. Hartley, Y. Kusumoto, Y. Fezoui, M.M. Condron, A. Lomakin, G.B.
Benedek, D.J. Selkoe, D.B. Teplow, Amyloid beta-protein ﬁbrillogenesis. Structure
and biological activity of protoﬁbrillar intermediates, J. Biol. Chem. 274 (1999)
25945–25952.
[6] M. Goedert, M.G. Spillantini, Molecular neuropathology of Alzheimer's disease: in
situ hybridization studies, Cell. Mol. Neurobiol. 10 (1990) 159–174.
[7] C. Pereira, P. Agostinho, P.I. Moreira, S.M. Cardoso, C.R. Oliveira, Alzheimer's
disease-associated neurotoxic mechanisms and neuroprotective strategies, Curr.
Drug Targets CNS Neurol. Disord. 4 (2005) 383–403.
[8] M.A. Smith, K.L. Drew, A. Nunomura, A. Takeda, K. Hirai, X. Zhu, C.S. Atwood, A.K.
Raina, C.A. Rottkamp, L.M. Sayre, R.P. Friedland, G. Perry, Amyloid-beta, tau
alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or
the eggs? Neurochem. Int. 40 (2002) 527–531.
[9] R. Thangavel, S.K. Sahu, G.W. Hoesen, A. Zaheer, Loss of nonphosphorylated
neuroﬁlament immunoreactivity in temporal cortical areas in Alzheimer's disease,
Neuroscience (2009).
[10] M.J. Ball, Neuroﬁbrillary tangles in the dementia of “normal pressure” hydro-
cephalus, Can. J. Neurol. Sci. 3 (1976) 227–235.
[11] C. Mori, E.T. Spooner, K.E. Wisniewsk, T.M. Wisniewski, H. Yamaguch, T.C. Saido,
D.R. Tolan, D.J. Selkoe, C.A. Lemere, Intraneuronal Abeta42 accumulation in Down
syndrome brain, Amyloid 9 (2002) 88–102.
[12] P. Fernandez-Vizarra, A.P. Fernandez, S. Castro-Blanco, J. Serrano, M.L. Bentura, R.
Martinez-Murillo, A. Martinez, J. Rodrigo, Intra- and extracellular Abeta and PHF
in clinically evaluated cases of Alzheimer's disease, Histol. Histopathol. 19 (2004)
823–844.
[13] P.A. Trimmer, P.M. Keeney, M.K. Borland, F.A. Simon, J. Almeida, R.H. Swerdlow, J.P.
Parks, W.D. Parker Jr., J.P. Bennett, Mitochondrial abnormalities in cybrid cell
models of sporadic Alzheimer's diseaseworsenwith passage in culture, Neurobiol.
Dis. 15 (2004) 29–39.
[14] R.H. Swerdlow, J.K. Parks, D.S. Cassarino, D.J. Maguire, R.S. Maguire, J.P. Bennett,
R.E. Davis, W.D. Parker, Cybrids in Alzheimer's disease: a cellular model of the
disease? Neurology 49 (1997) 918–925.
[15] G. Carrieri, M. Bonafe, M. De Luca, G. Rose, O. Varcasia, A. Bruni, R. Maletta, B.
Nacmias, S. Sorbi, F. Corsonello, E. Feraco, K.F. Andreev, A.I. Yashin, C. Franceschi, G.
De Benedictis, Mitochondrial DNA haplogroups and APOE4 allele are non-
independent variables in sporadic Alzheimer's disease, Hum. Genet. 108 (2001)
194–198.
[16] K. Takuma, J. Yao, J. Huang, H. Xu, X. Chen, J. Luddy, A.C. Trillat, D.M. Stern, O.
Arancio, S.S. Yan, ABAD enhances Abeta-induced cell stress via mitochondrial
dysfunction, Faseb J. 19 (2005) 597–598.
[17] J.N. Keller, Z. Pang, J.W. Geddes, J.G. Begley, A. Germeyer, G. Waeg, M.P. Mattson,
Impairment of glucose and glutamate transport and induction of mitochondrial
oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role
of the lipid peroxidation product 4-hydroxynonenal, J. Neurochem. 69 (1997)
273–284.
[18] H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H.
Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, S.D.
Yan, Cyclophilin D deﬁciency attenuates mitochondrial and neuronal perturbation
and ameliorates learning andmemory in Alzheimer's disease, Nat. Med. 14 (2008)
1097–1105.
[19] A.Y. Abramov, L. Canevari, M.R. Duchen, Beta-amyloid peptides induce mitochon-drial dysfunction and oxidative stress in astrocytes and death of neurons through
activation of NADPH oxidase, J. Neurosci. 24 (2004) 565–575.
[20] C. Caspersen, N. Wang, J. Yao, A. Sosunov, X. Chen, J.W. Lustbader, H. Wei Xu, D.
Stern, G. McKhann, S.D. Yan, Mitochondrial Abeta: a potential focal point for
neuronal metabolic dysfunction in Alzheimer's disease, FASEB J. 19 (2005)
2040–2041.
[21] C.S. Casley, L. Canevari, J.M. Land, J.B. Clark, M.A. Sharpe, Beta-amyloid inhibits
integrated mitochondrial respiration and key enzyme activities, J. Neurochem. 80
(2002) 91–100.
[22] H. Du, L. Guo, W. Zhang, M. Rydzewska, S. Yan, Cyclophilin D deﬁciency improves
mitochondrial function and learning/memory in aging Alzheimer disease mouse
model, Neurobiology of Aging (in press) [Epub ahead of print], doi:10.1016/j.
neurobiolaging.2009.03.003.
[23] S.M. Cardoso, S. Santos, R.H. Swerdlow, C.R. Oliveira, Functional mitochondria are
required for amyloid beta-mediated neurotoxicity, FASEB J. 15 (2001) 1439–1441.
[24] V. Chauhan, A. Chauhan, Oxidative stress in Alzheimer's disease, Pathophysiology
13 (2006) 195–208.
[25] T. Hosoda, H. Nakajima, H. Honjo, Estrogen protects neuronal cells from amyloid
beta-induced apoptotic cell death, Neuroreport 12 (2001) 1965–1970.
[26] C. Pereira, P. Agostinho, C.R. Oliveira, Vinpocetine attenuates the metabolic
dysfunction induced by amyloid beta-peptides in PC12 cells, Free Radic. Res. 33
(2000) 497–506.
[27] J.W. Lustbader, M. Cirilli, C. Lin, H.W. Xu, K. Takuma, N. Wang, C. Caspersen, X.
Chen, S. Pollak, M. Chaney, F. Trinchese, S. Liu, F. Gunn-Moore, L.F. Lue, D.G.Walker,
P. Kuppusamy, Z.L. Zewier, O. Arancio, D. Stern, S.S. Yan, H. Wu, ABAD directly links
Abeta to mitochondrial toxicity in Alzheimer's disease, Science 304 (2004)
448–452.
[28] K. Hensley, J.M. Carney, M.P. Mattson, M. Aksenova, M. Harris, J.F. Wu, R.A. Floyd,
D.A. Butterﬁeld, A model for beta-amyloid aggregation and neurotoxicity based
on free radical generation by the peptide: relevance to Alzheimer disease, Proc.
Natl. Acad. Sci. U. S. A. 91 (1994) 3270–3274.
[29] S. Morais Cardoso, R.H. Swerdlow, C.R. Oliveira, Induction of cytochrome c-
mediated apoptosis by amyloid beta 25–35 requires functional mitochondria,
Brain Res. 931 (2002) 117–125.
[30] S.M. Cardoso, I. Santana, R.H. Swerdlow, C.R. Oliveira, Mitochondria dysfunction of
Alzheimer's disease cybrids enhances Abeta toxicity, J. Neurochem. 89 (2004)
1417–1426.
[31] J.H. Chin, F.W. Tse, K. Harris, J.H. Jhamandas, Beta-amyloid enhances intracellular
calcium rises mediated by repeated activation of intracellular calcium stores and
nicotinic receptors in acutely dissociated rat basal forebrain neurons, Brain Cell
Biol. 35 (2006) 173–186.
[32] E. Ferreiro, C.R. Oliveira, C. Pereira, Involvement of endoplasmic reticulum Ca2+
release through ryanodine and inositol 1,4,5-triphosphate receptors in the
neurotoxic effects induced by the amyloid-beta peptide, J. Neurosci. Res. 76
(2004) 872–880.
[33] M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg, R.E. Rydel, Beta-Amyloid
peptides destabilize calcium homeostasis and render human cortical neurons
vulnerable to excitotoxicity, J. Neurosci. 12 (1992) 376–389.
[34] X. Wang, B. Su, S.L. Siedlak, P.I. Moreira, H. Fujioka, Y. Wang, G. Casadesus, X. Zhu,
Amyloid-beta overproduction causes abnormal mitochondrial dynamics via diffe-
rential modulation of mitochondrial ﬁssion/fusion proteins, Proc. Natl. Acad. Sci.
U. S. A. 105 (2008) 19318–19323.
[35] D.T. Chang, A.S. Honick, I.J. Reynolds, Mitochondrial trafﬁcking to synapses in
cultured primary cortical neurons, J. Neurosci. 26 (2006) 7035–7045.
[36] M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, P.H. Reddy, Mito-
chondria are a direct site of A beta accumulation in Alzheimer's disease neurons:
implications for free radical generation and oxidative damage in disease pro-
gression, Hum. Mol. Genet. 15 (2006) 1437–1449.
[37] G. Petrosillo, F.M. Ruggiero, M. Pistolese, G. Paradies, Ca2+-induced reactive
oxygen species production promotes cytochrome c release from rat liver mito-
chondria via mitochondrial permeability transition (MPT)-dependent and MPT-
independentmechanisms: role of cardiolipin, J. Biol. Chem. 279 (2004) 53103–53108.
[38] T.R. Rosenstock, A.C. Carvalho, A. Jurkiewicz, R. Frussa-Filho, S.S. Smaili,
Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative
disease model induced by 3-nitropropionic acid, J. Neurochem. 88 (2004)
1220–1228.
[39] M.F. Galindo, J. Jordan, C. Gonzalez-Garcia, V. Cena, Reactive oxygen species induce
swelling and cytochrome c release but not transmembrane depolarization in
isolated rat brain mitochondria, Br. J. Pharmacol. 139 (2003) 797–804.
[40] C.P. Baines, R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, M.A. Hambleton, E.W.
Brunskill, M.R. Sayen, R.A. Gottlieb, G.W. Dorn, J. Robbins, J.D. Molkentin, Loss of
cyclophilin D reveals a critical role for mitochondrial permeability transition in
cell death, Nature 434 (2005) 658–662.
[41] J.K. Parks, T.S. Smith, P.A. Trimmer, J.P. Bennett Jr., W.D. Parker Jr., Neurotoxic Abeta
peptides increase oxidative stress in vivo through NMDA-receptor and nitric-
oxide-synthase mechanisms, and inhibit complex IV activity and induce a mito-
chondrial permeability transition in vitro, J. Neurochem. 76 (2001) 1050–1056.
[42] H. Kroner, Ca2+ ions, an allosteric activator of calcium uptake in rat liver
mitochondria, Arch. Biochem. Biophys. 251 (1986) 525–535.
[43] E.J. Grifﬁths, Mitochondrial calcium transport in the heart: physiological and
pathological roles, J. Mol. Cell. Cardiol. 46 (2009) 789–803.
[44] M. Prentki, D. Janjic, C.B. Wollheim, The regulation of extramitochondrial steady
state free Ca2+ concentration by rat insulinoma mitochondria, J. Biol. Chem. 258
(1983) 7597–7602.
[45] A.P. Halestrap, What is the mitochondrial permeability transition pore? J. Mol.
Cell. Cardiol. 46 (2009) 821–831.
204 H. Du, S.S. Yan / Biochimica et Biophysica Acta 1802 (2010) 198–204[46] G.P. McStay, S.J. Clarke, A.P. Halestrap, Role of critical thiol groups on the matrix
surface of the adenine nucleotide translocase in the mechanism of the
mitochondrial permeability transition pore, Biochem. J. 367 (2002) 541–548.
[47] A.P. Halestrap, G.P. McStay, S.J. Clarke, The permeability transition pore complex:
another view, Biochimie 84 (2002) 153–166.
[48] A.P. Halestrap, The mitochondrial permeability transition: its molecular mecha-
nism and role in reperfusion injury, Biochem. Soc. Symp. 66 (1999) 181–203.
[49] I. Szabo, V. De Pinto, M. Zoratti, The mitochondrial permeability transition pore
may comprise VDACmolecules: II. The electrophysiological properties of VDAC are
compatible with those of the mitochondrial megachannel, FEBS Lett. 330 (1993)
206–210.
[50] A.P. Halestrap, K.Y. Woodﬁeld, C.P. Connern, Oxidative stress, thiol reagents, and
membrane potential modulate the mitochondrial permeability transition by
affecting nucleotide binding to the adenine nucleotide translocase, J. Biol. Chem.
272 (1997) 3346–3354.
[51] A.P. Halestrap, C.P. Connern, E.J. Grifﬁths, P.M. Kerr, Cyclosporin A binding to
mitochondrial cyclophilin inhibits the permeability transition pore and protects
hearts from ischaemia/reperfusion injury, Mol. Cell. Biochem.174 (1997) 167–172.
[52] L. Khaspekov, H. Friberg, A. Halestrap, I. Viktorov, T. Wieloch, Cyclosporin A and its
nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose/
oxygen deprivation-induced damage to rat cultured hippocampal neurons, Eur. J.
Neurosci. 11 (1999) 3194–3198.
[53] A. Krauskopf, O. Eriksson, W.J. Craigen, M.A. Forte, P. Bernardi, Properties of the
permeability transition in VDAC1(−/−) mitochondria, Biochim. Biophys. Acta
1757 (2006) 590–595.
[54] C.P. Baines, R.A. Kaiser, T. Sheiko, W.J. Craigen, J.D. Molkentin, Voltage-dependent
anion channels are dispensable for mitochondrial-dependent cell death, Nat. Cell.
Biol. 9 (2007) 550–555.
[55] J.E. Kokoszka, K.G. Waymire, S.E. Levy, J.E. Sligh, J. Cai, D.P. Jones, G.R. MacGregor,
D.C. Wallace, The ADP/ATP translocator is not essential for the mitochondrial
permeability transition pore, Nature 427 (2004) 461–465.
[56] A.W. Leung, P. Varanyuwatana, A.P. Halestrap, The mitochondrial phosphate
carrier interacts with cyclophilin D and may play a key role in the permeability
transition, J. Biol. Chem. 283 (2008) 26312–26323.
[57] M.J. Hansson, T. Persson, H. Friberg, M.F. Keep, A. Rees, T. Wieloch, E. Elmer,
Powerful cyclosporin inhibition of calcium-induced permeability transition in
brain mitochondria, Brain Res. 960 (2003) 99–111.
[58] S.J. Clarke, G.P. McStay, A.P. Halestrap, Sanglifehrin A acts as a potent inhibitor of
the mitochondrial permeability transition and reperfusion injury of the heart by
binding to cyclophilin-D at a different site from cyclosporin A, J. Biol. Chem. 277
(2002) 34793–34799.
[59] S.L. Siedlak, G. Casadesus, K.M. Webber, M.A. Pappolla, C.S. Atwood, M.A. Smith, G.
Perry, Chronic antioxidant therapy reduces oxidative stress in a mouse model of
Alzheimer's disease, Free Radic. Res. 43 (2009) 156–164.
[60] G.M. Bores, C.P. Smith, F. Wirtz-Brugger, A. Giovanni, Amyloid beta-peptides
inhibit Na+/K+-ATPase: tissue slices versus primary cultures, Brain Res. Bull. 46
(1998) 423–427.
[61] R.J. Mark, K. Hensley, D.A. Butterﬁeld, M.P. Mattson, Amyloid beta-peptide impairs
ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+
homeostasis and cell death, J. Neurosci. 15 (1995) 6239–6249.
[62] S.A. Price, B. Held, H.A. Pearson, Amyloid beta protein increases Ca2+ currents in
rat cerebellar granule neurones, Neuroreport 9 (1998) 539–545.
[63] F.J. Ekinci, K.U. Malik, T.B. Shea, Activation of the L voltage-sensitive calcium
channel by mitogen-activated protein (MAP) kinase following exposure of neu-ronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neuro-
degeneration, J. Biol. Chem. 274 (1999) 30322–30327.
[64] R.F. Cowburn, B. Wiehager, E. Trief, M. Li-Li, E. Sundstrom, Effects of beta-amyloid-
(25–35) peptides on radioligand binding to excitatory amino acid receptors and
voltage-dependent calcium channels: evidence for a selective afﬁnity for the
glutamate and glycine recognition sites of the NMDA receptor, Neurochem. Res. 22
(1997) 1437–1442.
[65] H. Hiruma, T. Katakura, S. Takahashi, T. Ichikawa, T. Kawakami, Glutamate
and amyloid beta-protein rapidly inhibit fast axonal transport in cultured
rat hippocampal neurons by different mechanisms, J. Neurosci. 23 (2003)
8967–8977.
[66] J.R. Lopez, A. Lyckman, S. Oddo, F.M. Laferla, H.W. Querfurth, A. Shtifman,
Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice,
J. Neurochem. 105 (2008) 262–271.
[67] J.H. Kim, J.C. Rah, S.P. Fraser, K.A. Chang, M.B. Djamgoz, Y.H. Suh, Carboxyl-terminal
peptide of beta-amyloid precursor protein blocks inositol 1,4,5-trisphosphate-
sensitive Ca2+ release in Xenopus laevis oocytes, J. Biol. Chem. 277 (2002)
20256–20263.
[68] P.I. Moreira, M.S. Santos, A. Moreno, A.C. Rego, C. Oliveira, Effect of amyloid beta-
peptide on permeability transition pore: a comparative study, J. Neurosci. Res. 69
(2002) 257–267.
[69] P.I. Moreira, M.S. Santos, A. Moreno, C. Oliveira, Amyloid beta-peptide pro-
motes permeability transition pore in brain mitochondria, Biosci. Rep. 21 (2001)
789–800.
[70] E.F. Shevtzova, E.G. Kireeva, S.O. Bachurin, Effect of beta-amyloid peptide fragment
25–35 on nonselective permeability of mitochondria, Bull. Exp. Biol. Med. 132
(2001) 1173–1176.
[71] R.A. Eliseev, G. Filippov, J. Velos, B. VanWinkle, A. Goldman, R.N. Rosier, T.E. Gunter,
Role of cyclophilin D in the resistance of brain mitochondria to the permeability
transition, Neurobiol. Aging. 28 (2007) 1532–1542.
[72] M.R. Brown, P.G. Sullivan, J.W. Geddes, Synaptic mitochondria are more
susceptible to Ca2+overload than nonsynaptic mitochondria, J. Biol. Chem. 281
(2006) 11658–11668.
[73] K.K. Naga, P.G. Sullivan, J.W. Geddes, High cyclophilin D content of synaptic
mitochondria results in increased vulnerability to permeability transition,
J. Neurosci. 27 (2007) 7469–7475.
[74] D.J. Selkoe, Alzheimer's disease is a synaptic failure, Science 298 (2002) 789–791.
[75] X. Yang, Y. Yang, G. Li, J. Wang, E.S. Yang, Coenzyme Q10 attenuates beta-amyloid
pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation,
J. Mol. Neurosci. 34 (2008) 165–171.
[76] J.S. Miners, S. Baig, J. Palmer, L.E. Palmer, P.G. Kehoe, S. Love, Abeta-degrading
enzymes in Alzheimer's disease, Brain Pathol. 18 (2008) 240–252.
[77] S. Schroeter, K. Khan, R. Barbour, M. Doan, M. Chen, T. Guido, D. Gill, G. Basi, D.
Schenk, P. Seubert, D. Games, Immunotherapy reduces vascular amyloid-beta in
PDAPP mice, J. Neurosci. 28 (2008) 6787–6793.
[78] C. Chipana, J. Camarasa, D. Pubill, E. Escubedo, Memantine prevents MDMA-
induced neurotoxicity, Neurotoxicology 29 (2008) 179–183.
[79] J. Diehl-Schmid, H. Forstl, R. Perneczky, C. Pohl, A. Kurz, A 6-month, open-label
study of memantine in patients with frontotemporal dementia, Int. J. Geriatr.
Psychiatry 23 (2008) 754–759.
[80] C. Fujisaki, M. Utsuyama, Y. Kuroda, A. Watanabe, H. Seidler, S. Watanabe, M.
Kitagawa, K. Hirokawa, An immnosuppressive drug, cyclosporine-A acts like anti-
depressant for rats under unpredictable chronic stress, J. Med. Dent. Sci. 50 (2003)
93–100.
